ストックスクリーナーアプリを入手
9.905
72.91%
-26.66
アフターアワーズ：
10.05
0.145
+1.46%
前日終値:
$36.56
開ける：
$12.98
24時間の取引高:
8.07M
Relative Volume:
15.22
時価総額：
$449.15M
収益：
-
当期純損益:
$-161.15M
株価収益率:
-2.6663
EPS:
-3.7149
ネットキャッシュフロー:
$-138.61M
1週間 パフォーマンス:
-72.48%
1か月 パフォーマンス:
-70.24%
6か月 パフォーマンス:
-48.28%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$9.905
$14.50
1週間の範囲:
$9.905
$38.26
52週間の値動き範囲:
$9.905
$40.43
Maplight Therapeutics Inc Stock (MPLT) Company Profile
名前
Maplight Therapeutics Inc
セクター
電話
650-839-4360
住所
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
9.905 | 1.66B | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-08 | 開始されました | Needham | Buy |
| 2026-04-07 | 開始されました | TD Cowen | Buy |
| 2026-03-19 | 開始されました | Canaccord Genuity | Buy |
| 2025-11-21 | 開始されました | Jefferies | Buy |
| 2025-11-21 | 開始されました | Leerink Partners | Outperform |
| 2025-11-21 | 開始されました | Morgan Stanley | Overweight |
| 2025-11-21 | 開始されました | Stifel | Buy |
すべてを表示
Maplight Therapeutics Inc (MPLT) 最新ニュース
MapLight Therapeutics Inc (MPLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose - Yahoo Finance
Morgan Stanley downgrades MapLight Therapeutics stock rating on trial results - Investing.com
Wolfe cuts MapLight Therapeutics stock price target on trial data - Investing.com
Wolfe cuts MapLight Therapeutics stock price target on trial data By Investing.com - Investing.com Canada
MapLight’s ZEPHYR Trial Hits Endpoints In Schizophrenia, But Investors Want To See More - insights.citeline.com
MapLight Therapeutics' Lead Candidate Falls Meaningfully Short In Schizophrenia (MPLT) - Seeking Alpha
MapLight’s Schizophrenia Candidate Has Mixed Results at Phase II - Inside Precision Medicine
Biotech And AI Stocks Got Hit On Mixed News - Finimize
Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint - MarketBeat
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
MapLight Therapeutics (MPLT) Faces Stock Decline Despite Positiv - GuruFocus
MapLight sinks as Cobenfy challenger falls short on once-daily goal - FirstWord Pharma
MapLight dives despite positive data for schizophrenia drug - BioPharma Dive
Maplight aims to differentiate muscarinic agonist from competitors - BioWorld News
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law - Business Wire
Maplight Therapeutics (NASDAQ:MPLT) Sets New 12-Month LowTime to Sell? - MarketBeat
MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout - BioSpace
MapLight Therapeutics stock holds Buy rating at TD Cowen after trial data - Investing.com
Jefferies reiterates MapLight Therapeutics stock rating on trial data - Investing.com
Raymond James cuts MapLight Therapeutics stock price target on efficacy data - Investing.com Canada
Jefferies reiterates MapLight Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
BMO reiterates Outperform on MapLight stock after trial data By Investing.com - Investing.com Canada
MapLight’s schizophrenia drug fails once-daily test, shares plunge - 101 WIXX
BMO reiterates Outperform on MapLight stock after trial data - Investing.com
Stifel reiterates MapLight Therapeutics stock rating on schizophrenia data By Investing.com - Investing.com Canada
Stifel reiterates MapLight Therapeutics stock rating on schizophrenia data - Investing.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
MPLT: ML-007C-MA met key efficacy and safety endpoints in Phase 2 schizophrenia trial, supporting Phase 3 plans - TradingView
Maplight Therapeutics Announces Positive Topline Results from Phase 2 Zephyr Trial of Ml-007C-Ma in Schizophrenia - marketscreener.com
MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data (MPLT:NASDAQ) - Seeking Alpha
MapLight schizophrenia drug meets phase 2 trial primary endpoint - Investing.com
MapLight Therapeutics stock tumbles 40% on trial results - Investing.com
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia - The Manila Times
MapLight Therapeutics (Nasdaq: MPLT) hits key Phase 2 goal in schizophrenia - Stock Titan
MapLight Therapeutics Inc (MPLT) Institutional Confidence - TradingKey
MapLight Therapeutics Inc (MPLT) Cash Flow - TradingKey
MPLT|MapLight Therapeutics Inc|Price:9.910|Chg%:-26.650 - TradingKey
MapLight Therapeutics Inc (MPLT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
MapLight Therapeutics (MPLT) Rally Puts Its CNS Story And Valuation In Focus - simplywall.st
MPLT|MapLight Therapeutics Inc|Price:36.560|Chg%:+1.330 - TradingKey
Is MapLight Therapeutics (MPLT) Fully Valued As Its Shares Hold Near $36.56? - Yahoo! Finance Canada
MapLight Therapeutics, Inc. Revenue Breakdown – NASDAQ:MPLT - TradingView
MAPLIGHT THERAPEUTICS INC : CANACCORD GENUITY RAISES TARGET PRICE TO $43 FROM $35 - webull.com
Canaccord raises MapLight Therapeutics price target on trial data By Investing.com - Investing.com South Africa
Canaccord raises MapLight Therapeutics price target on trial data - Investing.com
Possible Bearish Signals With MapLight Therapeutics Insiders Disposing Stock - simplywall.st
Craig-Hallum initiates coverage of MapLight Therapeutics (MPLT) with buy recommendation - MSN
Wall Street Analysts Are Bullish on Top NA Picks - The Globe and Mail
Maplight Therapeutics (NASDAQ:MPLT) Upgraded by BMO Capital Markets to Strong-Buy Rating - MarketBeat
Maplight Therapeutics Inc (MPLT) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):